Gut Microbiota
Conditions
Keywords
Gut Microbiota, Hashimoto Thyroiditis, Graves' Disease, Methimazole, Levothyroxine sodium, 16S rRNA gene, Metabonomics
Brief summary
Autoimmune thyroid disease (AITD), which includes Hashimoto's thyroiditis (HT) and Grave's disease (GD), are the most common organ-specific autoimmune diseases and affect more women than men, with a female-to-male ratio from 5 to 10. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in AITD patients and healthy controls.
Detailed description
Autoimmune thyroid disease (AITD), which includes Hashimoto's thyroiditis (HT) and Grave's disease (GD), are the most common organ-specific autoimmune diseases and affect more women than men, with a female-to-male ratio from 5 to 10. These two diseases are clinically diverse because in HT, T cells aid in the destruction of the thyroid epithelial cells (thyrocytes) and thyroid epithelial structure and eventual fibrous replacement of parenchymal tissue leading to hypothyroidism, whereas GD is primarily a humoral disease where auto-antibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism (2,163-165). However, these diseases still share several immunological features，and the disease may progress from one state to another as the autoimmune process evolves. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in AITD patients and healthy controls.
Interventions
DRUGMethimazole Pill
Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
Sponsors
First Affiliated Hospital of Harbin Medical University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 18 to 65 years * Male or female gender * Euthyroidism (normal FT3, FT4, and TSH plasma levels without hormonal therapy)
Exclusion criteria
* Pregnancy * Lactation * Cigarette smoking * Alcohol addiction * Hypertension * Diabetes mellitus * Lipid dysregulation * BMI \> 27 * Recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, proton pump inhibitors, insulin sensitizers or Chinese herbal medicine * Known history of disease with an autoimmune component such as MS, rheumatoid arthritis, IBS, and IBD * History of malignancy or any gastrointestinal tract surgery (e.g., gastrectomy, bariatric surgery, colectomy, ileectomy, cholecystectomy or appendectomy).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 16S rRNAgene sequencing was used to measure the diversity of gut microbiota | HC, treatment_naive HT and treatment_naive GD patients samples were collected at the enroll. Treated GD patients were collected until thyroid function resumed to the normal for at least 3 months of methimazole withdrawal | Intestinal microbes are different in different groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thyroid function tested by Chemiluminescence method | Treatment_naive GD and treatment_naive HT patients thyroid function were tested at the enroll and after 3 months | Serum results are different in different groups and different time point |
Other
| Measure | Time frame | Description |
|---|---|---|
| Thyroid relative antibody test by Chemiluminescence | Treatment_naive GD and treatment_naive HT patients thyroid function were tested at the enroll and after 3 months | Serum results are different in different groups and different time point |
Countries
China
Contacts
Primary ContactWei Yunwei
Outcome results
None listed